Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients

Published:2015-09-19 Issue:6 Volume:33 Page:1242-1247
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Baas J. M.,Krens L. L.,ten Tije A. J.,Erdkamp F.,van Wezel T.,Morreau H.,Gelderblom H.,Guchelaar H. J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-015-0285-8.pdf

Reference35 articles.

1. Denters MJ, Deutekom M, Fockens P, Bossuyt PM, Dekker E (2009) Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands. BMC Gastroenterol 9:28

2. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

3. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

4. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS (2014) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26:13–21

5. Krens LL, Baas JM, Gelderblom H, Guchelaar HJ (2010) Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discov Today 15:502–516

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statins as anti‐tumor agents: A paradigm for repurposed drugs;Cancer Reports;2024-05

2. Are statins onco- suppressive agents for every type of tumor? A systematic review of literature;Expert Review of Anticancer Therapy;2024-04-15

3. Cancer Metabolism as a Therapeutic Target and Review of Interventions;Nutrients;2023-10-01

4. Role of non-canonical post-translational modifications in gastrointestinal tumors;Cancer Cell International;2023-09-30

5. Repositioning of HMG-CoA Reductase Inhibitors as Adjuvants in the Modulation of Efflux Pump-Mediated Bacterial and Tumor Resistance;Antibiotics;2023-09-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3